The CDC announcement backtracked on its previous interim estimates in March for 2021 to 2022 seasonal influenza found that the vaccine did not offer significant immunity, with estimated immune protection of 16 percent. “Seasonal influenza vaccination did not reduce the risk for outpatient respiratory illness,” wrote the authors of the March study. Nonetheless, the same authors also encouraged the uptake of influenza vaccines despite insignificant scientific evidence of benefit, with a projected vaccine uptake of 188 to 200 million doses among Americans. Though CDC claims that recent flu vaccine efficacy hovered in the range of 40 to 60 percent efficacy, other reports have shown a 30 to 40 percent vaccine efficacy instead, way below the recommended level for vaccine efficacy.
The CDC now says that the influenza vaccine offers moderate protection against the virus by reducing mild to moderate symptoms by 35 percent. The World Health Organization’s website wrote that vaccines need to have at least 50 percent efficacy to be approved; this statement is in stark contrast to the reality of approved vaccines with vaccine efficacy dropping below 50 percent, sometimes with even insignificant efficacy. Declining Flu Vaccination Rates: An Aftermath of COVID-19 Vaccination
Since February, data from the CDC has shown that vaccination uptake has seen a significant drop for the 2021 to 2022 season, even for those that are of “increased risk of flu complications.” Similar results have also been observed in a study by the University of California, finding a drop in influenza vaccination rate to be the most significant in states that had low COVID-19 vaccination rates. They suggest that the drop in influenza vaccination may have been due to the public’s attitudes toward COVID-19 spilling into public health. Those that think unfavorably of COVID-19 vaccines may also extend these sentiments to other vaccines administered by the general health care sector.
“Many Americans who never before declined a routine, potentially life-saving vaccine have started to do so,” said the study’s lead author Dr. Richard Leuchter in the university’s media release. The authors proposed “belief generalization” as the reason, giving the example of how someone may not wear a mask to signal their beliefs publicly, those that oppose or support the COVID-19 vaccine may also “feel that they should, in turn, oppose or support other vaccines.” Though the study did not make any direct associations between specific influenza vaccination decreases with pandemic policies and the promotion of COVID-19 vaccines, it indicated that “safety concerns and mistrust of COVID-19 vaccines or government” may have been factors associated with the COVID-19 vaccination rates and the decrease in influenza vaccine uptake." CDC Updates Flu Vax Efficacy: Negligible Immunity Increases to Moderate 35 Percent Efficacy (theepochtimes.com)
Quote: "Pfizer Plans To Profit From Covid For Years To Come. Pfizer has already profited billions of dollars from the COVID-19 pandemic, and it plans to do so for years to come via annual vaccinations and sales of its antiviral pill Paxlovid. The company doubled its revenue from 2020 to 2021, bringing in more than $81 billion, and also gained a large foothold in the American regulatory process, according to Kaiser Health News. CEO Albert Bourla and other top executives have said they plan to continue taking advantage of the COVID-19 market for the foreseeable future. “Hopefully, we could be giving it annually and maybe for some groups that are high-risk more often,” Bourla told investors earlier this year, referring to COVID-19 booster shots and vaccines tailored to specific variants. “Then you have the treatment [Paxlovid] that will, let’s say, resolve the issues of those that are getting the disease.” Some patients have experienced issues with “rebound” infections with Paxlovid, cases where they begin experiencing stronger symptoms again after completing their series of the antiviral pill. That won’t stop Pfizer from selling millions more doses though, executives said.
"People are going to get out there,” the president of Pfizer Biopharmaceuticals Group, Angela Hwang, said in May. “We know with all of that, infections are going to increase, and that’s the role that Paxlovid can play.” In that investor call, Dr. Mikael Dolsten described immunocompromised patients as an “opportunity growth area.” The company is now approaching Paxlovid’s failure to neutralize the virus as an opportunity to give patients more courses. “[They] may carry this virus for a very, very long time,” he said. “And we see that area as a real new opportunity growth area for Paxlovid to do very well, where you may need to take multiple courses.”
In addition to making more than a projected $50 billion in revenue in 2022 from the vaccine and Paxlovid, Pfizer is now exerting an outsized influence over federal agencies like the Food and Drug Administration (FDA), according to Kaiser. Leaders at the company have often been ahead of public health officials when it comes to guiding the response to the pandemic, such as when Bourla announced in the summer of 2021, months before public health officials, that Americans would likely soon need a booster shot. Bourla was also several months ahead of the FDA in suggesting that Americans will need annual booster shots. Profitability could surge even further. Bourla said the price of both Pfizer’s COVID-19 vaccine and Paxlovid will increase in the future, once society is past the pandemic period to “reflect the cutting-edge technology.”
Another way Pfizer has exerted influence over the federal government is via political donations. It made around $3 million in donations during the 2020 election cycle, more than any other drug company. It has also spent more than $25 million in lobbying, going to 19 different firms, since early 2020. In addition to the billions already spent on COVID-19 vaccines, the Biden administration just made a purchase of $3.2 billion for this year’s fall vaccination campaign and has bought 20 million courses of Paxlovid at more than $500 a pop, according to Kaiser." Pfizer Plans to Profit from Covid for Years to Come - Truth Press
No comments:
Post a Comment